Bio-Rad Laboratories, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: NYS:BIO
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 40 out of 847
Universe
Global Universe 2625 out of 15035
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
QIAGEN NV |
13.4
Low
|
10 out of 847 |
Revvity, Inc. |
15.6
Low
|
23 out of 847 |
Avantor, Inc. |
16.6
Low
|
38 out of 847 |
Bio-Rad Laboratories, Inc. |
16.8
Low
|
40 out of 847 |
Medpace Holdings, Inc. |
17.2
Low
|
44 out of 847 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Bio-Rad Laboratories, Inc.'s Exposure is Low
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Bio-Rad Laboratories, Inc.'s Management of ESG Material Risk is Average
How do the ESG Risk Ratings work?
Top Material ESG Issues for Bio-Rad Laboratories, Inc.
Understand how exposed companies are to specific material ESG issues and how well companies are managing these issues.
What are Material ESG Issues?
Material ESG issues are issues that are considered to be financially material to a given company in a relevant sub-industry.
Controversy Rating
Highest Controversy level that has impacted Bio-Rad Laboratories, Inc.'s ESG Risk Rating in the last three years
Highest Controversy Level